CR9759A - Vacuna rotavirus que induce la proteccion cruzada heterotipica - Google Patents

Vacuna rotavirus que induce la proteccion cruzada heterotipica

Info

Publication number
CR9759A
CR9759A CR9759A CR9759A CR9759A CR 9759 A CR9759 A CR 9759A CR 9759 A CR9759 A CR 9759A CR 9759 A CR9759 A CR 9759A CR 9759 A CR9759 A CR 9759A
Authority
CR
Costa Rica
Prior art keywords
heterotipic
rotavirus vaccine
rotavirus
vaccine inducing
crossed
Prior art date
Application number
CR9759A
Other languages
English (en)
Inventor
Desiree Alberte Colau Brigitte
Arsen Virginie De Vos Beatrice
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516944A external-priority patent/GB0516944D0/en
Priority claimed from GB0521164A external-priority patent/GB0521164D0/en
Priority claimed from GB0608962A external-priority patent/GB0608962D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CR9759A publication Critical patent/CR9759A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invencion proporciona un procedimiento de induccion de una respuesta inmune contra una cepa de rotavirus, comprendiendo el procedimiento la administracion a un sujeto de una composicion que comprende una cepa de rotavirus atenuado de un tipo GxPy, generando dicha composicion una respuesta inmune contra una cepa de rotavirus que ni es un tipo Gx ni Py.
CR9759A 2005-08-17 2008-02-22 Vacuna rotavirus que induce la proteccion cruzada heterotipica CR9759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0516944A GB0516944D0 (en) 2005-08-17 2005-08-17 Vaccine
GB0521164A GB0521164D0 (en) 2005-10-18 2005-10-18 Vaccine
GB0608962A GB0608962D0 (en) 2006-05-05 2006-05-05 Vaccine

Publications (1)

Publication Number Publication Date
CR9759A true CR9759A (es) 2008-05-05

Family

ID=37757924

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9759A CR9759A (es) 2005-08-17 2008-02-22 Vacuna rotavirus que induce la proteccion cruzada heterotipica

Country Status (25)

Country Link
US (1) US20090028828A1 (es)
EP (2) EP2233153B1 (es)
JP (1) JP5519934B2 (es)
KR (1) KR20080036648A (es)
AR (1) AR054916A1 (es)
AU (1) AU2006281566B2 (es)
BR (1) BRPI0615203A2 (es)
CA (1) CA2619751C (es)
CR (1) CR9759A (es)
CY (1) CY1116135T1 (es)
DK (1) DK2233153T3 (es)
EA (1) EA014328B1 (es)
ES (1) ES2534637T3 (es)
HR (1) HRP20150310T1 (es)
IL (1) IL189289A0 (es)
MA (1) MA29700B1 (es)
MX (1) MX2008002270A (es)
NO (1) NO20080754L (es)
PE (1) PE20070235A1 (es)
PL (1) PL2233153T3 (es)
PT (1) PT2233153E (es)
SG (1) SG163571A1 (es)
SI (1) SI2233153T1 (es)
TW (1) TW200740457A (es)
WO (1) WO2007020078A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
WO2009042202A2 (en) 2007-09-25 2009-04-02 Aridis Pharmaceuticals Formulations for preservation of rota virus
US9311112B2 (en) * 2009-03-16 2016-04-12 Apple Inc. Event recognition
BR112013027457A2 (pt) * 2011-04-28 2019-09-24 Int Medica Foundation preparação de vacina, e, métodos de fabricar uma preparação de vacina, e de vacinar um mamífero
CN110227152A (zh) * 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69130068T2 (de) * 1990-11-16 1999-01-07 Children's Hospital Medical Center, Cincinnati, Ohio Humane rotativen, impfstoffe und methoden
UA77388C2 (uk) * 1999-08-17 2006-12-15 Глаксосмітклайн Байолоджікалз С.А. Послаблена популяція ротавірусів людини, ротавірус та вакцинна композиція, що містить живий послаблений ротавірус людини
EP1660123B1 (en) * 2003-09-02 2013-03-13 GlaxoSmithKline Biologicals s.a. Rotavirus vaccine

Also Published As

Publication number Publication date
CY1116135T1 (el) 2017-02-08
WO2007020078A3 (en) 2007-05-24
PE20070235A1 (es) 2007-04-04
KR20080036648A (ko) 2008-04-28
MX2008002270A (es) 2008-03-27
CA2619751A1 (en) 2007-02-22
EP1915173A2 (en) 2008-04-30
TW200740457A (en) 2007-11-01
DK2233153T3 (da) 2015-04-27
AU2006281566B2 (en) 2011-09-01
SG163571A1 (en) 2010-08-30
AU2006281566A1 (en) 2007-02-22
AR054916A1 (es) 2007-07-25
EA014328B1 (ru) 2010-10-29
IL189289A0 (en) 2008-06-05
JP2009504701A (ja) 2009-02-05
US20090028828A1 (en) 2009-01-29
PL2233153T3 (pl) 2015-06-30
EP2233153B1 (en) 2015-01-21
BRPI0615203A2 (pt) 2011-05-10
SI2233153T1 (sl) 2015-05-29
PT2233153E (pt) 2015-04-20
ES2534637T3 (es) 2015-04-27
HRP20150310T1 (hr) 2015-06-19
NO20080754L (no) 2008-05-15
MA29700B1 (fr) 2008-08-01
WO2007020078A2 (en) 2007-02-22
JP5519934B2 (ja) 2014-06-11
EA200800320A1 (ru) 2008-10-30
CA2619751C (en) 2016-07-05
EP2233153A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
CR9759A (es) Vacuna rotavirus que induce la proteccion cruzada heterotipica
JO3257B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
ECSP077179A (es) Co-cultivos manejados de organismos que tienen efectos profilacticos y promotores de la salud
AR075169A1 (es) Capas de saccharomyces cerevisiae con aptitudes fitosanitarias
CO6160335A2 (es) Vacuna
CR10347A (es) Anticuerpos contra el peptidob-amiloide
TW200806316A (en) Yeast-based vaccine for inducing an immune response
BRPI0815008B8 (pt) vacinas multiméricas com múltiplos epítopos contra influenza
TW200603825A (en) Prrsv subunit vaccines
MX2009003378A (es) Concentrados en suspension para la mejora de la absorcion por la raiz de principios activos agroquimicos.
BRPI0821240B8 (pt) formas mutantes de estreptolisina o
EA201400510A1 (ru) Водная фотозащитная композиция для личной гигиены
AR056712A1 (es) Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus
PH12015501875A1 (en) Acellular pertussis vaccine
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
AR052639A1 (es) Composicion vacunal contra el virus de la hepatitis c.
PH12017550047A1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
WO2009044272A3 (en) Laser-based vaccine adjuvants
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
MX2012002630A (es) Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul.
CL2009000965A1 (es) Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmaceuticamente aceptable, que comprende ademas de un agente aglutinante, un desintegrante, un diluyente; proceso de preparacion de la tableta; y su uso en el tratamiento de vih y enfermedades inflamatorias.
CR20110501A (es) Composiciones para la protección de cosechas, método para su aplicación y uso de dichas composiciones para protección de cosechas
Ahmed et al. Hepatoprotective fraction from aerial parts of Delonix regia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)